Matt Abernethy, Chief Financial Officer at Neurocrine Biosciences, sold NBIX on Sep 14, 2026
Data as of Oct 16
▼ SELL$363K2,311 shares at $157.20Matt Abernethy Chief Financial OfficerNBIX Neurocrine Biosciences Inc
- Traded
- Sep 14, 2026
- Disclosed
- Sep 15, 2026
- Filed
- 1 day after the trade
Form 4s are due within two business days.
Official filing (SEC Form 4) ↗
The price around the disclosure
NBIX since disclosure
−9.5%
after the sale
Similar stocks (XLV) since disclosure
+5.4%
XLV — its sector index fund
Change in closing price from Sep 15, 2026 (the first trading day on or after disclosure) to Oct 16, 2026. Dividends excluded. Not a return anyone earned.
Our take
None of our tested rules fired on this trade.